Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor.

Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor. Abstract Text:

Y Tomino,T Yamazaki,I Shou,T Tsuge,K Satake,Y Takeda,A Ohtani,T Nishitani,A Kurusu,C Hamada,S Horikoshi,K Maeda,Y Tanaka,H Fukuda,M Wakabayashi,T Seto,

Aims: In this study, dose-response of the serum potassium-lowering effect of a calcium polystyrene sulfonate (PS) preparation was investigated. Changes in the serum potassium level were also examined with or without application of a RAAS inhibitor, which is said to increase the serum potassium level. Subjects and methods: 23 patients diagnosed to have hyperkalemia associated with chronic renal failure were enrolled in this study. The study drug, a PS-Ca jelly preparation (Argamate jelly), was started at a daily dose of 1 preparation (5 g as PS-Ca), and the dose was increased by 1 preparation every month to finally reach 3 preparations per day. Blood samples were collected once a month and serum levels of creatinine and electrolytes were measured. Results: PS-Ca jelly decreased serum potassium levels in a dose-dependent manner. Decreases were 0.67 mEq/l at 5 g of PS-Ca/day, 1.06 mEq/l at 10 g/d, and 1.33 mEq/l at 15 g/d. Irrespective of the use of the RAAS inhibitor, serum potassium levels decreased significantly in a dose-dependent manner. Furthermore, no major change in serum creatinine levels occurred in subjects in which the RAAS inhibitor was used, although in subjects in which the RAAS inhibitor was not used, serum creatinine level tended to gradually increase. Conclusion: Serum potassium levels were reduced in a dose-dependent manner by administration of 5 â 15 g/d of PS-Ca, and it appeared that together with control of serum potassium levels, renal function should be maintained by continuous administration of RAAS inhibitor.

Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor. Publishing Authors By Initials

Y Tomino,T Yamazaki,I Shou,T Tsuge,K Satake,Y Takeda,A Ohtani,T Nishitani,A Kurusu,C Hamada,S Horikoshi,K Maeda,Y Tanaka,H Fukuda,M Wakabayashi,T Seto,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical nephrology

VOLUME: 68

Page Numbers: 379-85

Journal Abbreviation: Clin. Nephrol.

ISSN: 0301-0430

DAY: 10

MONTH: Dec

YEAR: 2007

Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 364441

Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor.

AFFILIATION: 1Department of Internal Medicine, Division of Nephrology, Juntendo University School of Medicine, 2Division of Nephrology, Juntendo Nerima Hospital, Tokyo, 3Division of Nephrology, Juntendo Shizuoka Hospital, Nagaoka, Izunokuni City, Shizuoka, Japan.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Nephrol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor Related Publications

• Antihypertensive adherence and drug class among Asian Pacific Americans.
• Comparative specificity of geranylgeranyl pyrophosphate synthetase of Micrococcus lysodeikticus and pumpkin.
• Comparative studies of Aal allotypic specificity in IgG and IgM of rabbits. I. Demonstration and characterization of Aal allotypic determinants specific for IgG.
• Comparative studies of Aal allotypic specificity in IgG and IgM of rabbits. II. Phenotypic expression of allotypic specificities in rabbits exposed in neonatal life to antibodies directed against Aal allotypic determinants specific for IgG.
• Cytokine and clinical predictors for treatment outcome of visually guided temporomandibular joint irrigation in patients with chronic closed lock.
• Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia â changes in serum potassium levels with or without a RAAS inhibitor.
• Dural arteriovenous fistula involving the transverse sigmoid sinus after treatment: assessment with magnetic resonance digital subtraction angiography.
• Efferent pathways from the region of the subfornical organ to hypothalamic paraventricular nucleus: an electrophysiological study in the rat.
• Epidemiology and genetic diversity of methicillin-resistant Staphylococcus aureus strains in residential care homes for elderly persons in Hong Kong.
• Histone deacetylase 3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression.
• Inhibitory effect of substrate analogs on isopentenyl pyrophosphate isomerase and prenyltransferase.
• Intracranial dural arteriovenous fistulas: evaluation with combined 3D time-of-flight MR angiography and MR digital subtraction angiography.
• Laboratory pilot scale study for H(2)S removal from biogas in an anoxic biotrickling filter.
• Limitation of the peptide C-terminal tritium labelling method.
• Paget disease involving the left third metacarpal.
• Practical approaches to incidental findings in brain imaging research.
• Recurrent Adult Wilms Tumor With Extensive Metastases on FDG PET-CT.
• Socioeconomic considerations regarding a land mine victim with maxillofacial injuries.
• Structure-activity studies of cyclic ketone inhibitors of the serine protease plasmin: design, synthesis, and biological activity.
• Studies on Terpenoids Produced by Actinomycetes: Oxaloterpins A, B, C, D, and E, Diterpenes from Streptomyces sp. KO-3988.
• TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma.
• The National Institute of Biomedical Imaging and Bioengineering marks its first five years.
• The purification and properties of geranylgeranyl pyrophosphate synthetase from pumpkin fruit.
• The purification of prenyltransferase and isopentenyl pyrophosphate isomerase of pumpkin fruit and their some properties.
• Trisomy 3 is a specific genomic aberration of t(14;18) negative follicular lymphoma.
• Triterpenoids from Cimicifugae rhizoma, a novel class of inhibitors on bone resorption and ovariectomy-induced bone loss.
• Two forms of farnesyl pyrophosphate synthetase from hog liver.
• Ventrolateral medullary neurons projecting to the medial preoptic/anterior hypothalamic area through the medial forebrain bundle: an electrophysiological study in the rat.
• [A successful surgical repair of acute postinfarction mitral papillary muscle rupture]
• [Uropepsin in several surgical diseases with special reference to its variance through the operation.]